It is possible that further engineering of CAR(2448) T cells to deliver a therapeutic payload such as IL-12 or IL-18 upon recognition of target cells will be sufficient for tumour clearance, via the remodelling of the tumour microenvironment and the recruitment of innate immune cell populations to the tumour site [34]. This evidence concerns the gene IL18 and neoplasm.